Unlock instant, AI-driven research and patent intelligence for your innovation.

Attenuated oncolytic paramyxoviruses encoding avian cytokines

A cytokine and virus technology, applied in the direction of cytokines/lymphokines/interferons, viruses, sexual diseases, etc., to achieve the effect of reducing pathogenicity

Inactive Publication Date: 2011-06-15
BAYER SCHERING PHARMA OY
View PDF17 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

None of these recombinant NDVs were constructed for the treatment of human disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Attenuated oncolytic paramyxoviruses encoding avian cytokines
  • Attenuated oncolytic paramyxoviruses encoding avian cytokines
  • Attenuated oncolytic paramyxoviruses encoding avian cytokines

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0231] Generation of recombinant NDVs with avian-derived transgenes that cause chicken cytokine expression

[0232] Viral RNA was obtained using the oncolytic strain MTH68 of NDV. Using RT-PCR, several cDNA fragments were obtained and assembled in a multi-step cloning method into full-length genomic cDNA, which was cloned into the vector pX8δT (Schnell et al., 1994), resulting in plasmid pflMTH68. This vector can be used for transfection to rescue recombinant virus from cell lines expressing T7-polymerase.

[0233] An additional transcription cassette was cloned into a single Sfil restriction site between the genes encoding the F and HN proteins in the NDV MTH68 full-length genomic plasmid (pflMTH68). Two DNA oligonucleotides, Sfi forward (5'-aggccttaattaaccgacaacttaagaaaaaatacgggtagaacggcctgag-3', SEQ ID NO: 1) and Sfi reverse (5'-aggccgttctacccgtattttttcttaagttgtcggttaattaaggcctctc-3', SEQ ID NO: 2) were renatured and subsequently ligated to into the SfiI site of pflMTH68....

Embodiment 2

[0237] ChIFN-α and ChIFN-β expressed from recombinant NDV are biologically active

[0238] Materials and Methods:

[0239] CEC-32 cells (avian quail cell line) or Hela cells (cervical cancer cell line) were plated at 1x10 5 cells / well were plated in 6-well plates. After cell attachment, cells were infected with GFP-expressing control viruses NDV-GFP, NDV-ChIFN-alpha, NDV-ChIFN-beta or mock virus using an MOI of 0.01. After 64 hours, the supernatant was harvested and infectious viral particles were inactivated by UV irradiation.

[0240] To show the biological activity of ChIFN-α or ChIFN-β in supernatants of virus-infected cells, a chicken interferon-specific bioassay was used (Schwarz et al., JICR, 2005). The assay is based on the stably transfected quail cell line CEC-511, which carries the luciferase gene under the control of the IFN-responsive chicken Mx promoter. Luciferase activity was induced when CEC-511 indicated cells were incubated with ChIFN-α or ChIFN-β. To c...

Embodiment 3

[0248] Avian cells but not tumor cells infected with recombinant NDV expressing ChIFN-α or ChIFN-β are protected from viral lysis

[0249] Materials and Methods:

[0250] 3a.) CEC-32 cells (avian quail cell line) or Hela cells (cervical cancer cell line) were treated with 1×10 5 cells / well were plated in 6-well plates. After becoming adherent, cells were infected with the control virus NDV-GFP, NDV-ChIFN-alpha, NDV-ChIFN-beta or mock virus at an MOI of 0.01. After 48 hours, cells were fixed with 4% formaldehyde solution and stained with Giemsa solution. Subsequent photodocumention was then performed with a Zeiss Axiophot imaging system.

[0251] 3b.) CEC-32 cells (avian quail cell line) or Hela cells (cervical cancer cell line) were plated at 15,000 cells / well in a 96-well plate. After becoming adherent, cells were infected with control virus NDV-GFP, NDV-ChIFN-α, NDV-ChIFN-β or mock virus (=none) at MOI of 0.01. After a 48-hour incubation time, proceed to CellTiter- Lu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention refers to a recombinant oncolytic RNA Newcastle Disease Virus for the treatment of a proliferative disease, comprising at least one transgene coding for an avian cytokine, wherein the recombinant oncolytic RNA Newcastle Disease Virus is obtainable from a velogenic or mesogenic oncolytic RNA Newcastle Disease Virus. Virus-mediated expression of the cytokine in the natural host cells leads to a reduced pathogenicity of the virus for avian species. Furthermore the virus genome can encode binding proteins, prodrug-converting enzymes or / and proteases. The selective expression of these molecules in virus-infected tumor cells increases the anti-tumor effect of the virus.

Description

[0001] Introduction [0002] The present invention relates to a recombinant oncolytic RNA Newcastle disease virus comprising at least one transgene encoding an avian cytokine, wherein the recombinant oncolytic RNA Newcastle disease virus can be transformed from a virulent or mesogenic oncolytic RNA Newcastle disease virus get. In native host cells, virus-mediated cytokine expression results in reduced pathogenicity of the virus to avian species. [0003] The viruses of the present invention are suitable for the treatment of diseases, especially for oncolytic tumor therapy. Recombinant viruses encoding avian cytokines were generated with reduced pathogenicity to avian species, resulting in reduced environmental toxicity of the virus. The oncolytic activity of the virus was not compromised by the method of reducing pathogenicity. The viral genome may encode additional therapeutic transgenes, preferably binding proteins (antibodies, ankyrin repeat molecules, peptides, etc.). T...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/76A61K35/768
CPCA61K38/00C12N2760/18132C07K14/56C12N2760/18161C12N7/00C07K14/565C12N2760/18143C12N15/86A61K35/76A61K35/13A61K35/768A61K48/00A61P15/00A61P31/12A61P35/00A61P43/00A61K2300/00
Inventor R·拜尔F·普勒
Owner BAYER SCHERING PHARMA OY